FORMULATION AND EVALUATION OF NOVEL INSITU GEL SYSTEM IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS
DOI:
https://doi.org/10.22159/ijap.2022v14i5.43792Keywords:
Lornoxicam, Rheumatoid arthritis, In situ gels, Sodium alginate, ChitosanAbstract
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dosing frequency in the treatment of rheumatoid arthritis.
Methods: The method of ion-sensitive in-situ gel formation was used in this study. Lornoxicam in situ gel formulations were prepared by varying concentrations of sodium alginate as a bio-degradable gel-forming polymer, CaCl2 as a cross-linking agent, and chitosan, HPMCK4, HPMCK15, guar gum, gellan gum, xanthan gum, pectin were used as drug release rate controlling polymers. The formulations F11-F18 were assessed for physical appearance, pH, in vitro drug release, viscosity, in vitro gelling capacity, and drug content. FTIR, DSC, and in vivo drug kinetics studies were conducted for lornoxicam pure drug and optimized formulation.
Results: Formulations showed an optimum viscosity that will allow ease of administration and swallowing. All formulations were shown pH between 6.7 to 7.3, floating lag time was 2-3 sec and floated for 12 h. In vitro, drug release studies were reporting that commercial sustained release formulation of lornoxicam released 99.92% drug in 8 h, and optimized formulation F11 released 99.52% of the drug over a 12 h extended period. FTIR studies revealed no interaction between drugs and excipients used. The results of in vivo kinetic studies are approving the better performance of the optimized formulation. The Cmax, Tmax, t1/2, and AUC values are confirming the same thing.
Conclusion: Lornoxicam oral in situ gel containing chitosan as a drug release controlling polymer is a promising approach for the treatment of rheumatoid arthritis in a convenient dosage form with better patient compliance and therapeutic response.
Downloads
References
Chopra A. Ayurvedic medicine and arthritis. Rheum Dis Clin North Am. 2000;26(1):133-44. doi: 10.1016/s0889-857x(05)70127-7, PMID 10680201.
Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003;17(5):811-29. doi: 10.1016/s1521-6942(03)00048-2, PMID 12915159.
Pai DR, Venkatesh MP, Kumar TMP. Current developments in therapeutic drug targeting for the management of rheumatoid arthritis: an emerging paradigm. Crit Rev Ther Drug Carrier Syst. 2019;36(6):485-536. doi: 10.1615/CritRevTherDrugCarrierSyst.2019025729, PMID 32421953.
Misra R, Sharma B, Gupta R, Pandya S, Agarwal S, Agarwal P. Indian rheumatology association consensus statement on the management of adults with rheumatoid arthritis. Indian J Rheumatol. 2008;3(3):S1-S16. doi: 10.1016/S0973-3698(10)60373-1.
Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis. 1998;47(8):2-7. PMID 9926484.
Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440. doi: 10.1146/annurev.immunol.14.1.397, PMID 8717520.
Butoescu N, Jordan O, Doelker E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm. 2009;73(2):205-18. doi: 10.1016/j.ejpb.2009.06.009, PMID 19545624.
Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27(8):864-72. doi: 10.1002/art.1780270805, PMID 6431998.
Byrav DS, Medhi B, Prakash A, Patyar S, Wadhwa S. Lornoxicam: a newer NSAID. Int J Pharm Med Research. 2009;20:27-31.
Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity. 2011;1(1):28-44. doi: 10.15256/joc.2011.1.4, PMID 29090134.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-51. doi: 10.1016/j.amjopharm.2007.12.002, PMID 18179993.
Stubbs J, Haw C, Dickens G. Dose form modification– a common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr. 2008;20(3):616-27. doi: 10.1017/S1041610207006047, PMID 17711606.
Sivasubramanian L, Lakshmi KS, Tintu T. Simultaneous spectrophotometric estimation of paracetamol and lornoxicam in the tablet dosage form. Int J Pharm Sci. 2010;2:166.
Mahak S, Aarti M, Vishnu Y, Gopkumar P, Sridevi G. Formulation and evaluation of floatable in situ gel for stomach-specific drug delivery of venlafaxine hydrochloride. Res Rev J Pharm Pharm Sci. 2014;3:41-8.
Tawfeek HM, Saleem IY, Roberts M. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets. J Pharm Sci. 2014;103(8):2470-83. doi: 10.1002/jps.24073, PMID 24995853.
Kajale AD, Chandewar AV. Formulation development, and evaluation of oral floating in-situ gel of Ilaprazole. Pharm Sin. 2016;7:51-63.
Yehia SA, Abdel Halim SA, Aziz MY. Formulation and evaluation of injectable in situ forming microparticles for sustained delivery of lornoxicam. Drug Dev Ind Pharm. 2017;43(2):319-28. doi: 10.1080/03639045.2016.1241259, PMID 27671477.
Jitender Mor, Parveen Chauhan, Pawan Jalwal. Development and evaluation of oral fast dissolving tablets of lornoxicam using super disintegrants-a comparative study. The Pharm Innov J. 2016;5:1-7.
Vaibhav Mhasal, Sumedh Moharil N, Bhakti Mali, Mahesh Nark Hae B. Drug excipient study of lornoxicam with polymers. Scholars Acad J Pharm. 2017;6:423-8.
Prasanthi S, Vidyavathi M. Formulation and optimization of the buoyant in situ gelling system of valsartan using natural polymer. Int J Pharm Pharm Syst. 2017;10:128-36.
Madan JR, Adokar BR, Dua K. Development and evaluation of in situ gel of pregabalin. Int J Pharm Investig. 2015;5(4):226-33. doi: 10.4103/2230-973X.167686, PMID 26682193.
Anuja TK, Rahul J, Pradnya BS, Satwashila SK. Design and evaluation of modified chitosan-based ocular drug delivery. Int J Pharm Pharm Sci. 2017;9:87-91.
Maheswaran A, Padmavathy J, Nandhini V, Saravanan D, Angel P. Formulation and evaluation of floating oral in situ gel of diltiazem hydrochloride. Int J App Pharm. 2017;9(1):50-3. doi: 10.22159/ijap.2017v9i1.15914.
Mulagada S, Baratam SR. Design and evaluation of ondansetron fast disintegrating tablets using natural polymers and modified starches as super disintegrants for the enhancement of dissolution. J Young Pharm. 2017;9:19-24.
Chaudhary B, Verma S. Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections. Scientific World Journal. 2014;2014:280928. doi: 10.1155/2014/280928. PMID 24790559.
Monica RPR, Swapnil US, Aafaque Y. Controlled release floating oral in situ gel of itopride hydrochloride using pH-sensitive polymer. IJPPS. 2014;6:338-43.
M SS, Priya S, Maxwell A. Formulation and evaluation of novel in situ gel of lafutidine for gastro retentive drug delivery. Asian J Pharm Clin Res. 2018;11(8):88-94. doi: 10.22159/ajpcr.2018.v11i8.25582.
Sangeetha S, Harish G, Ramya M, Prasanthi G, Raju B, Damodharan N. Oral sustained delivery of salbutamol using in situ gelation of sodium alginate. Int J Curr Pharm Res. 2010;2:61-4.
AS, Ahmed MG, Gowda Bh J. Preparation and evaluation of in situ gels containing hydrocortisone for the treatment of aphthous ulcer. J Oral Biol Craniofac Res. 2021;11(2):269-76. doi: 10.1016/j.jobcr.2021.02.001, PMID 33717865.
Thomas LM. Formulation and evaluation of floating oral in situ gel of metronidazole. Int J Pharm Pharm Sci. 2014;6:265-9.
Sathiyaraj S, Devi RD, Hari VB. Lornoxicam gastro retentive floating matrix tablets: design and in vitro evaluation. J Adv Pharm Technol Res. 2011;2(3):156-62. doi: 10.4103/2231-4040.85531, PMID 22171312.
Harish NM, Prabhu P, Charyulu RN, Gulzar MA, Subrahmanyam EVS. Formulation and evaluation of in situ gels containing clotrimazole for oral candidiasis. Indian J Pharm Sci. 2009;71(4):421-7. doi: 10.4103/0250-474X.57291, PMID 20502548.
Published
How to Cite
Issue
Section
Copyright (c) 2022 B. PADMASRI, R. NAGARAJU
This work is licensed under a Creative Commons Attribution 4.0 International License.
